Company Performance Metrics
- Connor Bernstein: Vice President of Strategy & Corporate Development
- Liz Doolin: Vice President Clinical Development
Bionomics Limited engages in the discovery and development of therapeutics for cancer and diseases of the central nervous system in Australia. It has small molecule product development programs in the areas of cancer, anxiety, epilepsy, and multiple sclerosis. The company develops its lead cancer compound, BNC 105, for the treatment of solid
tumors, such as breast, lung, colon, and prostate cancers. BNC 105 is a member of the class of compounds, known as vascular disruption agents or VDAs, which shut down the blood supply within a tumor, starving the tumor and preventing its continued growth.
The company has commercial partnerships with Genmab A/S; Athena Diagnostics; Laboratory Corporation of America; and Genetic Technologies, Ltd. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia.
